Meta Pharmaceuticals, a Shenzen, China-based immunometabolism-based small-molecule drug discovery company, raised $15M in funding.
Forcefield Ventures and XtalPi Inc. led the round. IMO Ventures and Tiantu Capital also participated.
The company intends to use the funds to accelerate its three candidates toward clinical trials and further expand its proprietary platform to cover more disease areas as it continues to grow its pipeline, expand its team and establish its first biology laboratory in Shenzhen, China, to further strengthen its research capabilities in immunometabolism and drive target discovery.
Led by CEO Dr. Ke Xu, Meta Pharmaceuticals is a drug discovery company focused on autoimmune diseases that has built an AI-powered metabolic target discovery platform and aims to develop the next generation of safer and more effective autoimmune disease medicines based on new biological mechanisms. The company discovered a number of targets for autoimmune diseases based on new biology theories. These target diseases can be used to regulate the immune system’s functions and manipulate the vitality of the cellular metabolism.
It created an AI-enabled multi-omics-based platform for target discovery for metabolic pathways. The platform is called METAMAP and can scan through thousands upon thousands of metabolic protases in order to identify specific therapeutic effects. The team identified a number of druggable targets that had first-in class potential. They also developed a pipeline of three small molecule inhibitors. One of these is a candidate to treat a wide range of autoimmune diseases. It is expected to file for INDs in the US and China by 2024.
Meta Pharmaceuticals formed a partnership with XtalPi (an AI drug discovery platform company) to speed up drug discovery. Both AI platforms are able to create an efficient and reliable validation loop for new therapeutic targets. It also accelerates the translation of these targets into patents or pipeline assets.